FGFR

Cat. No.

A33572

CAS No.

2488764-17-4

FGFR-IN-7

FGFR-IN-7 is a potent fibroblast growth factor receptor modulator with oral bioavailability and effective blood-brain barrier penetration. It exhibits neuroprotective activity, making it a valuable tool for studying neurodegenerative diseases. Its ability to enhance brain exposure while reducing the risk of phospholipidosis emphasizes its potential in therapeutic applications related to CNS disorders.

Cat. No.

A33573

CAS No.

2727083-99-8

CXF-007

CXF-007 is a selective inhibitor of fibroblast growth factor receptor 4 (FGFR4) with an IC50 value of 7 nM. This compound demonstrates significant antitumor activity, making it a valuable tool for cancer research. Its specificity for FGFR4 positions it as a key reagent for studying FGFR4-mediated signaling pathways and exploring therapeutic options in FGFR4-driven malignancies.

Cat. No.

A33575

CAS No.

442534-83-0

FGFR1 inhibitor-14

FGFR1 inhibitor-14 is a selective inhibitor targeting the Fibroblast Growth Factor Receptor 1 (FGFR1). This compound demonstrates significant anti-proliferative activity in various cancer cell lines, making it a valuable tool in cancer research. It is particularly useful for studies focused on the role of FGFR1 signaling in tumorigenesis and therapeutic response.

Cat. No.

A33576

CAS No.

3025799-28-1

FGFR2/3-IN-2

FGFR2/3-IN-2 is a potent inhibitor of FGFR2 and FGFR3, demonstrating IC50 values of 3.7 nM and 31.2 nM, respectively, following a one-hour preincubation. This compound selectively inhibits FGFR2 and FGFR3 without affecting FGFR1/4 or other kinases, minimizing undesirable side effects such as diarrhea and elevated serum phosphate in vivo. FGFR2/3-IN-2 effectively induces tumor stasis or regression in the SNU-16 gastric cancer model, making it a valuable tool for research in cancer biology and targeted therapy.

Cat. No.

A33580

CAS No.

1035270-44-0

AZ8010

Synonyms: AZ12908010

AZ8010 is a selective inhibitor targeting fibroblast growth factor receptors 1 to 3 (FGFR1-3). It exhibits significant anti-proliferative activity, making it a valuable tool for cancer research. This compound can be utilized in studies exploring FGFR-related signaling pathways and their implications in tumorigenesis.

Cat. No.

A33581

CAS No.

459137-97-4

FGFR1 inhibitor-15

FGFR1 inhibitor-15 is a selective inhibitor of Fibroblast Growth Factor Receptor 1 (FGFR1), exhibiting an IC50 value of 27 μM. This compound is valuable for cancer research, facilitating the investigation of FGFR1 signaling pathways and their implications in tumor growth and development. Its use can contribute to the understanding of FGFR1-related oncogenic mechanisms and the potential for therapeutic targeting in malignancies.

Cat. No.

A33582

CAS No.

606958-57-0

FGFR1 inhibitor-16

FGFR1 Inhibitor-16 is a selective inhibitor of Fibroblast Growth Factor Receptor 1 (FGFR1). This compound demonstrates an inhibitory efficacy of 53.00% at a concentration of 50 μM and 24.95% at 10 μM. FGFR1 Inhibitor-16 is valuable for research applications focused on cancer, allowing for the exploration of FGFR1 signaling pathways and their roles in tumor biology.

Cat. No.

A33583

CAS No.

308298-51-3

FGFR1 inhibitor-17

FGFR1 inhibitor-17 is a potent inhibitor targeting fibroblast growth factor receptor 1 (FGFR1). This compound demonstrates significant anti-proliferative activity in various cancer models, making it a valuable tool for cancer research. Its ability to inhibit FGFR1 signaling pathways can aid in the investigation of tumor biology and the development of targeted therapies.

Cat. No.

A33585

CAS No.

848463-13-8

SSR128129E free acid

Synonyms: SSR free acid

SSR128129E free acid is an allosteric inhibitor of fibroblast growth factor receptors (FGFR), exhibiting an IC50 of 1.9 μM for FGFR1. This compound demonstrates significant biological activity in modulating FGFR signaling pathways, making it valuable for research into cancer and other diseases associated with FGFR dysregulation. Its oral availability further facilitates in vivo studies and therapeutic exploration.

Cat. No.

A33587

CAS No.

943189-02-4

FGFR-IN-12

FGFR-IN-12 is a selective inhibitor of the Fibroblast Growth Factor Receptor (FGFR). This pyrimidinyl aryl urea derivative exhibits potent inhibition of FGFR activity, making it a valuable tool for investigating pathways involving FGFR signaling. Its efficacy positions FGFR-IN-12 as a significant compound for research applications related to cancer biology and therapeutic development targeting FGFR-related diseases.

Cat. No.

A33590

CAS No.

2847066-15-1

Segigratinib hydrochloride

Synonyms: 3D185; HH185

Segigratinib hydrochloride is a selective inhibitor of FGFR1, FGFR2, FGFR3, and CSF-1R, exhibiting IC50 values of 0.5 nM, 1.3 nM, 3.6 nM, and 3.8 nM, respectively. This compound demonstrates significant antitumor activity, making it a valuable tool for cancer research. Its ability to target multiple receptors involved in tumor progression highlights its potential for therapeutic applications in oncology.

Cat. No.

A75530

CAS No.

34539-65-6

β,β-Dimethylacrylalkannin

Synonyms: Arnebin 1

β,β-Dimethylacrylalkannin is a potent inhibitor of Fibroblast Growth Factor Receptor 1 (FGFR1) with an IC50 value of 2.5 μM. By binding to the ATP pocket of FGFR1, it effectively disrupts downstream signaling pathways, leading to G2/M phase cell cycle arrest and subsequent necrosis and apoptosis in various cancer cell lines. This compound shows promising therapeutic potential in the treatment of malignancies such as hepatocellular carcinoma and colorectal cancer. Additionally, it serves as an adjuvant in the treatment of colistin-resistant Gram-negative bacterial infections, making it valuable for research in cancer therapy and antimicrobial resistance.

Cat. No.

B22012

CAS No.

2833703-74-3

FGFR3-IN-10

FGFR3-IN-10 is a selective inhibitor of fibroblast growth factor receptor 3 (FGFR3), demonstrating significantly enhanced specificity for FGFR3 compared to FGFR1. This compound is primarily utilized in cancer research and has applications in studying systemic sclerosis, fibrosis, and pulmonary fibrosis. Additionally, FGFR3-IN-10 is relevant for investigating genetic conditions such as achondroplasia, thanatophoric dysplasia, and severe achondroplasia with developmental delay, as well as Muenke syndrome and acanthosis nigricans (SADDAN).

Cat. No.

K10003

3i Stem Cell Reprogramming and Maintenance Kit

Synonyms: 3i Cocktail; 3i Kit; CHIR-99021/SU5402/PD184352; iPSC Reprogramming Inhibitor Kit; Ground State Inhibitor Kit; CHIR99021; SU 5402; CI-1040

A set of three small-molecule inhibitors (CHIR-99021, SU5402 and PD184352) for the reprogramming and long-term maintenance of induced pluripotent stem cells under 3i conditions. One kit supplements up to 3 L of culture medium.